Clinical Trials Browser

Recruiting × Interventional × belzutifan × Clear all

Carcinoma, Carcinoma, Renal Cell

NCT04924075 2026-02-24

MK-6482-015

Phase 2 Recruiting

322 enrolled 1 FDA

CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT07049926 2026-02-19

MK-3475-03C

Phase 1/2 Recruiting

140 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT02861573 2026-02-17

KEYNOTE-365

Phase 1/2 Recruiting

1,200 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT06234605 2026-01-15

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Phase 1 Recruiting

80 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT07187778 2026-01-05

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

Phase 2 Recruiting

10 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT06428396 2025-12-26

LITESPARK-029

Phase 2 Recruiting

120 enrolled

Breast

Breast Neoplasms

NCT06677190 2025-11-05

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

Phase 2 Recruiting

32 enrolled

Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT07179770 2025-09-23

Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

Phase 1 Recruiting

12 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma

NCT07167329 2025-09-11

BELIEVE-VHL

Phase 2 Recruiting

100 enrolled

CNSEndocrineGenitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma, Neuroectodermal Tumors, Primitive, Hemangioblastoma

Clinical Trials

LITESPARK-033

MK-6482-015

MK-3475-03C

KEYNOTE-365

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

LITESPARK-029

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

BELIEVE-VHL